帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tertiary lymphoid structure-related score as a predictor for survival prognosis and immunotherapy response in head and neck squamous cell carcinoma.
Tertiary lymphoid structure-related score as a predictor for survival prognosis and immunotherapy response in head and neck squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们的研究提出了一种 TLS 的预测模型,该模型能够评估 HNSSC 患者中 TLS 的存在情况,并预测其生存预后和免疫治疗反应。此外,我们鉴定出一种特定的 T 细胞亚型,可能有助于阐明 TLS 在抗肿瘤活动中发挥功能的机制。这种 T 细胞亚型有望在未来成为预后标志物和过继性细胞疗法(ACT)的靶点。
大量研究表明,三级淋巴结构(TLS)与多种癌症的预后和免疫治疗反应相关。然而,TLS的预测价值、TLS内特定的免疫细胞亚型及其抗肿瘤机制仍不清楚。
基于23个TLS相关基因(TLSRGs),我们利用生物信息学方法构建了一个评分系统,命名为TLSscore。通过整合RNA和单细胞测序数据,我们评估了TLSscore在头颈部鳞状细胞癌(HNSCC)中的实用性。采用流式细胞术分选分离特定的T细胞亚型,并进行体内和体外实验以证明其抗肿瘤作用。
构建了TLSscore模型,并发现特定的TLSscore基因与TLS的空间位置一致。TLSscore已被证明是一个稳健的预测模型,可用于预测生存预后、免疫细胞浸润、体细胞突变和免疫治疗反应。值得注意的是,在TLS中鉴定出一种特定的PD1 + CXCL13 + CD8 + T细胞亚型。体内和体外实验均表明,PD1 + CXCL13 + CD8 + T细胞可能代表一种在免疫监视过程中发挥抗肿瘤作用的功能性细胞亚型。
Substantial studies reveal that tertiary lymphoid structure (TLS) correlate with prognosis and immunotherapy response in various types of cancers. However, the predictive value of TLS, the specific immune cell subtype within TLS and their anti-tumor mechanisms remain unclear.
Based on 23 TLS-related genes (TLSRGs), we utilized bioinformatics methods to construct a scoring system, named TLSscore. By integrating RNA and single-cell sequencing data, we assessed the utility of TLSscore in head and neck squamous cell carcinoma (HNSCC). Flow cytometric sorting was used to isolate specific T cells subtypes, in vivo and in vitro experiments were conducted to demonstrate its anti-tumor effects.
The TLSscore model was constructed and specific TLSscore-genes were found to consistently align with the spatial location of TLS. TLSscore has proven to be a robust predictive model for predicting survival prognosis, immune cell infiltration, somatic mutation and immunotherapy response. Notably, a specific PD1 + CXCL13 + CD8 + T cell subtype was identified within TLS. Both in vivo and in vitro experiments demonstrated that PD1 + CXCL13 + CD8 + T cell might represent a functional cell subtype exerting anti-tumor effects during the process of immune surveillance.
Our study presents a predictive model for TLS, which can evaluate its presence and predicts survival prognosis and immunotherapy response in HNSSC patients. Additionally, we identify a specific subtype of T cells that might elucidate the mechanism of TLS function in anti-tumor activities. This T cell subtype holds the potential to be a prognostic marker and a target for adoptive cell therapy (ACT) in the future.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。